NASDAQ · Biotechnology

MacroGenics, Inc. (MGNX) Stock

$3.75 +5.49% NASDAQ: MGNX Healthcare

Valuation

MetricValue
Price$3.75
Market Cap$238.04M
P/E Ratio-16.25
P/B Ratio5.30
P/S Ratio1.36
EPS (TTM)$-1.33
52-Week High$5.08
52-Week Low$1.29
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-31.27%
ROA-4.22%
ROCE-17.22%
Gross Margin69.93%
Operating Margin-40.53%
Net Margin-8.70%
Debt/Equity0.82
Current Ratio5.12

Annual Financials (USD)

Metric20212022202320242025
Revenue$76.0M$150.0M$57.0M$148.0M$150.0M
Operating Profit$-203.0M$-121.0M$-168.0M$-111.0M$-73.0M
Net Profit$-202.0M$-120.0M$-9.0M$-67.0M$-75.0M
EPS$-3.37$-1.95$-0.15$-1.07$-1.18
Op Margin-268.1%-80.9%-294.2%-74.5%-48.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$335.0M$290.0M$298.0M$262.0M$257.0M
Total Liabilities$96.0M$147.0M$146.0M$146.0M$201.0M
Cash$123.0M$109.0M$101.0M$183.0M$57.0M
Borrowings$25.0M$35.0M$34.0M$37.0M$107.0M

Latest News

R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy Insider Monkey · Jul 5, 2026 VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone Exec Edge · Jul 2, 2026 MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals MT Newswires · Jul 2, 2026 MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy? Zacks · Jul 2, 2026 Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations ACCESS Newswire · Jul 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-144.0M$-87.0M$-78.0M$-68.0M$-81.0M
Investing Cash Flow$-43.0M$67.0M$-82.0M$146.0M$-116.0M
Financing Cash Flow$5.0M$1.0M$149.0M$-2.0M$69.0M
Net Cash Flow$-58.0M$-15.0M$-8.0M$82.0M$-126.0M
Free Cash Flow$-150.0M$-91.0M$-80.0M$-72.0M$-83.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.13
EV / EBITDA-1.82
FCF Yield-28.84%
Quick Ratio2.96
Interest Coverage-2.41
Return 1Y121.55%
Return 3Y-16.98%
Return 5Y-82.60%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLNNClene Inc. $3.87 -0.26% -1.10 $49.45M 0.00%
CNTBConnect Biopharma Holdings Limited $0.91 +3.44% -1.05 $57.36M 0.00%
CNTXContext Therapeutics Inc. $0.30 +1.10% -0.64 $27.78M 0.00%
COYACoya Therapeutics, Inc. $4.97 -0.50% -4.53 $116.46M 0.00%
IFRXInflaRx N.V. $1.60 +4.58% -3.14 $235.67M 0.00%

About MacroGenics, Inc.

MacroGenics, Inc. is led by CEO Eric Blasius Risser, publicly traded since 2013.

MacroGenics, Inc. (MGNX) stock trades at $3.75 with a market capitalization of $238.04M. The stock is valued at a price-to-earnings (P/E) ratio of -16.25, price-to-book of 5.30, price-to-sales of 1.36. Over the past 52 weeks the stock has ranged between $1.29 and $5.08, and currently trades 26.2% below its 52-week high.

On profitability, MacroGenics, Inc. generates a return on equity (ROE) of -31.27%, return on capital employed of -17.22%, an operating margin of -40.53%, a net profit margin of -8.70%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1178.52 +0.76% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.57 +2.24% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.42 +2.28% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $657.76 +0.89% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides